HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 446 shares, a growth of 792.0% from the July 15th total of 50 shares. Based on an average daily trading volume, of 1,133 shares, the short-interest ratio is presently 0.4 days.
HLS Therapeutics Stock Performance
HLTRF traded down $0.23 on Tuesday, reaching $2.75. 200 shares of the stock were exchanged, compared to its average volume of 876. The company’s 50-day moving average price is $3.06 and its 200 day moving average price is $3.22. HLS Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $4.02.
About HLS Therapeutics
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
See Also
- Five stocks we like better than HLS Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
